Next Article in Journal
Can Novel Treatment of Age-Related Macular Degeneration Be Developed by Better Understanding of Sorsby’s Fundus Dystrophy
Next Article in Special Issue
Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications
Previous Article in Journal
Neuroendocrine Disturbances after Brain Damage: An Important and Often Undiagnosed Disorder
Previous Article in Special Issue
Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?
Open AccessReview

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics

Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY 10029, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Sebastien Barbarot and Kim Thomas
J. Clin. Med. 2015, 4(5), 858-873; https://doi.org/10.3390/jcm4050858
Received: 16 March 2015 / Revised: 20 April 2015 / Accepted: 21 April 2015 / Published: 29 April 2015
(This article belongs to the Special Issue Epidemiology and Treatment of Atopic Eczema)
Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD. View Full-Text
Keywords: atopic dermatitis; eczema; biomarker; translational revolution; T-cells; intrinsic; extrinsic; immune phenotype atopic dermatitis; eczema; biomarker; translational revolution; T-cells; intrinsic; extrinsic; immune phenotype
MDPI and ACS Style

Mansouri, Y.; Guttman-Yassky, E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J. Clin. Med. 2015, 4, 858-873.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop